Search Results

Sherlock Biosciences today announced the enrollment of the first participant in the PROMISE Study, a multicenter clinical study to evaluate the performance of the Sherlock STI over-the-counter (OTC) disposable molecular test against the gold standard of central lab PCR testing.

Sherlock Biosciences today announced that veteran research and development executive Maurice Exner has been appointed as the company’s first Chief Scientific Officer.

Sherlock Biosciences today announced the acquisition of Sense Biodetection (Sense), a global molecular diagnostics innovator.

Sherlock Biosciences today announced that it has received additional funding from the Bill & Melinda Gates Foundation to advance its rapid, instrument-free molecular diagnostic testing platform.

Sherlock Biosciences today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme, establishing Sherlock as the leader in CRISPR-based diagnostics with freedom to operate in the U.S. Sherlock has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, plus additional intellectual property (IP) for Cas12 and Cas13 from the Broad Institute, giving the company the preeminent IP position in the space.

Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, today announced it has signed a licensing agreement with Shanghai-based Tolo Biotech.

Sherlock Biosciences today announced that industry veteran Karen Davies has been appointed to its executive team as Chief Development Officer.

Funding led by Novalis LifeSciences to develop novel diagnostic products, powered by Sherlock’s proprietary platform leveraging CRISPR and synthetic biology.

Bryan Dechairo, newly appointed president and CEO of Sherlock Biosciences, learned early to fill gaps and seize opportunities. Read more about his views.